Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

Phase 3pemvidutidePositive

AI Analysis

Summary

Altimmune has initiated the PERFORMA Phase 3 trial to evaluate pemvidutide in patients with MASH, with endpoints focused on fibrosis improvement, MASH resolution, and clinical outcomes.

Clinical Trial Data

Phase

Importance:6/10

Sentiment:

0.50

Phase 3MASHfibrosistrial initiationpemvidutide

Related Companies

$GBCYD

Read the original article

Published by GlobeNewswire Clinical Studies on August 3, 2026 12:00 PM

Read Original